Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on BioRestorative Therapies (BRTX – Research Report). The associated price target is $10.00.
Michael Okunewitch’s Buy rating for BioRestorative Therapies is based on a comprehensive evaluation of early clinical data and the potential market impact of their innovative therapies. The company’s core product, BRTX-100, has shown promising results in a safety run-in portion of a Phase 2 study for chronic lumbar disk disease (CLDD). Initial findings suggest that the product is not only safe and well-tolerated but also potentially more effective than current treatments, including analgesics and other non-hypoxically cultured mesenchymal stem cell therapies. This positive preliminary safety and efficacy profile is a significant factor contributing to the Buy recommendation.
The blinded data from the Phase 2 study’s safety run-in revealed that three out of four subjects experienced substantial improvements in pain and functional rating scales, an indication of the treatment’s efficacy. Although caution is advised due to the small sample size and the blinded nature of the data, the observed outcomes align with expectations for a robust therapeutic effect. The improvements were measured using several patient-reported outcome measures, with the responder group showing reductions that exceeded the 30% response criteria set for the study’s endpoints. Such early indicators of success are instrumental in Okunewitch’s optimistic outlook for the stock, as they bode well for the results of the full enrollment in the ongoing Phase 2 study.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
BioRestorative Therapies (BRTX) Company Description:
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Read More on BRTX:
- BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
- BioRestorative Therapies Clarifies Disclosure Liability Limits
- BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
- BioRestorative presents preliminary data from Phase 2 study of BRTX-100
- BioRestorative Therapies Unveils BRTX-100 Clinical Trial Data
